We have been selected to evaluate an innovative therapy in this terrible disease. We will begin a Ib Phase clinical trial to evaluate the safety of an antiTau monoclonal antibody. If it is positive, we will participate in the development of the phase II trial to also check the efficacy and safety of different doses of this drug.
